Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques. - Wikidata - awgldk - TriplyDB

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.

http://www.wikidata.org/entity/Q35001598

about

Interleukin-15 biology and its therapeutic implications in cancer The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Developing Combined HIV Vaccine Strategies for a Functional Cure Targeting Strategies for Renal Cell Carcinoma: From Renal Cancer Cells to Renal Cancer Stem Cells The shared and contrasting roles of IL2 and IL15 in the life and death of normal and neoplastic lymphocytes: implications for cancer therapy Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy.Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8(+) T cells Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency.Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1 NK cells: immune cross-talk and therapeutic implications.IL-15 administered by continuous infusion to rhesus macaques induces massive expansion of CD8+ T effector memory population in peripheral blood Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia Transmembrane-Bound IL-15-Promoted Epithelial-Mesenchymal Transition in Renal Cancer Cells Requires the Src-Dependent Akt/GSK-3β/β-Catenin Pathway.Exercise-stimulated interleukin-15 is controlled by AMPK and regulates skin metabolism and aging.IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma Insulin-dependent diabetes induced by pancreatic beta cell expression of IL-15 and IL-15Rα Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model.IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor αSu/Fc fusion complex in syngeneic murine models of multiple myeloma Identification of IFN-γ-producing T cells as the main mediators of the side effects associated to mouse interleukin-15 sustained exposure Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.The new normal: immunomodulatory agents against sepsis immune suppression.Use of allogeneic NK cells for cancer immunotherapy.Immunotherapeutic applications of IL-15.Current strategies in immunotherapy for acute myeloid leukemia.IL-15 Agonists: The Cancer Cure Cytokine.Clinical utility of natural killer cells in cancer therapy and transplantation.Assessment of the metabolism of therapeutic proteins and antibodies.Interleukin-15 in the treatment of cancer.

P2860

Q24595605-06B1556A-7BF5-49BF-8AAE-9C23E05A21A8 Q24599103-438B62D1-2FFB-45B2-AF20-459EBA8BCD4B Q26797345-4CB62DE8-4FF4-44ED-960E-8303E77FC1CC Q26998898-CEF84875-4E25-4513-B5AA-42335C0AF2A0 Q28078154-69186867-8E95-40AC-8AA5-B95349AC6558 Q28088784-346CB33A-2FA3-42EC-B98D-E4CAEA31A8E5 Q28652428-540B86CD-88FB-4453-A64A-9AEE7F2C1917 Q33418729-29024A34-A9AD-441A-ABAF-44DCD02E1A82 Q33434322-0E671324-B4D4-43C2-A62A-637097E01D46 Q33785788-DB3552C4-9592-4BF8-A4D9-3218BC9F9F23 Q33905311-E68580D5-97EA-4073-A16C-3EFA609AFB5E Q34539858-DADF41AC-23BA-4FBB-AAD9-519B71ABC835 Q34708192-13728552-51C8-4C30-A51C-4BC117BAC7E5 Q34936507-CB138CB1-4800-4D72-AD6D-F50C7026E1D1 Q35060701-00CE1D7C-8532-4777-BC4B-3B7AC1A3B14C Q35591444-9049B20E-0F0D-444C-83C2-40F4DD0154F5 Q35631305-868D2E92-820B-4B3D-9141-4325A9AEDF9B Q35651700-9282F306-2CED-4BAE-A7CF-5587C37F7982 Q35745099-2100ADA8-FB50-4C1E-989F-1C5585EE4730 Q35935174-5D242A97-BFAC-4C62-A19D-A6335D313147 Q35979037-2A536E68-0B70-412C-AEC0-43EAC01D6536 Q36016369-533721C2-E829-4E72-9E82-1AD9A6EF25DC Q36079820-33FF013D-2461-4B13-9EE5-1F93ACE4B76C Q36416387-AFF0F792-F63E-4C58-83B9-50000F0361D4 Q36436914-0988D2E4-4A34-4E28-9850-EDCF8A52DFC7 Q36956269-FEF9918B-FB3F-4008-84F5-DB585D6DDDD1 Q37103886-85074EDC-59F3-4ED6-81D3-FA59A97B39CD Q37178190-65017A58-9612-4F1C-A83E-66E0378CD4E2 Q37261189-6BB8642D-EF15-4EB5-92EE-A6386C2E3369 Q37557639-C123380A-ED38-4835-99C6-3CD07EF2C567 Q37580158-777AAD0E-D07F-4364-943D-80B63F950F8D Q37650740-0CD3B81C-9698-4EA7-A774-B3196791FC15 Q37686624-59C8F734-1BFA-4936-AC35-BCBC20EB952D Q37957140-5F7434F6-85F7-44E4-BEF4-7B632A05EBB6 Q38050510-D8B3CDCF-9EEB-4E24-A1A6-01581C87ECF1 Q38068967-9F011C84-7192-44B4-8C4B-BFC496F09C4F Q38192628-69DAD363-58CA-4E54-AF28-8D2A8E3421B5 Q38195120-30133400-85FB-4447-9A6B-8F670D2E9236 Q38217623-3326F6F9-8E14-4F08-989B-3E8B981C4E5D Q38264072-B966C0AE-68ED-4F5C-988B-7A83E4D3030D

P2860

Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques.

http://www.wikidata.org/entity/Q35001598

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@ast

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@en

type

label

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@ast

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@en

prefLabel

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@ast

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@en

P1433

Q35001598-BDCC5B22-9E78-4099-97B0-0C8331317288

P1476

Q35001598-55713DC0-1BBD-43CC-A03C-2BB2BAD9E79C

P2093

Q35001598-0054DC67-BF90-4340-9B6F-8916CEB91C02

Q35001598-0D4D6B6D-9064-44D4-9D5F-E20464860535

Q35001598-11C88A23-033A-4C36-8FB0-1C33F63B92B3

Q35001598-497EA072-3515-4C49-A9EA-AC49118C0C46

Q35001598-8EA93F54-1C39-493B-963F-61B512F428EA

Q35001598-959A67E5-309D-4225-AAD1-A5AADC2F7C45

Q35001598-A4D52E42-832D-437B-BBA2-E042920DD644

Q35001598-A766169A-7303-4647-B26F-0E3D54FBDA47

Q35001598-A7EC19AC-C28E-47FC-A486-64DFFD3D683F

Q35001598-AB0C5D27-1229-438F-BD83-CC7581880D38

P2860

Q35001598-037EB8B3-BD41-4130-BA18-53FBFFA1E778

Q35001598-05DC4713-2456-4CA9-BDF1-59F186293A5E

Q35001598-07F869CD-E465-4D35-A416-B28B4E75BA20

Q35001598-08394D25-1FE7-43F0-A814-9D56920F6411

Q35001598-0C2C044B-4146-4942-BEF0-C1FD6F036FDF

Q35001598-0EBA9258-0C41-4068-AC79-2B83CF59BA53

Q35001598-14B57A6B-0283-4C54-947A-B6CEC891F094

Q35001598-1E6D2D36-ED47-4E59-B9E9-0C802EC63290

Q35001598-202776D6-16EE-4196-9238-0413CDE69AB9

Q35001598-25B45148-2FAC-4DF5-9C83-A82366127AD7

P304

Q35001598-D573E6F9-C2E1-4C03-84DA-EA101CFBF5FE

P31

Q35001598-E9D0D823-C2C3-41FD-B890-63EB420A1197

P356

Q35001598-4A9DF7C1-3A6B-4ED5-A7FD-66E68D25AB37

P407

Q35001598-E0E725B3-C391-47E8-B356-51EE503A606B

P433

Q35001598-036552EA-C8B5-411D-85A4-BB7DD7EBA788

P478

Q35001598-8104B8AB-A483-4481-A2C6-88D8F2FCDE9F

P50

Q35001598-0857214A-3F9D-4645-9D78-5F67B573786B

Q35001598-BDD70276-7D1B-4717-90AC-5CCC15CEDC5A

P577

Q35001598-873E1268-91BE-4603-A5BF-7E866BFEB4AD

P5875

Q35001598-DA55FD91-66E5-4904-B55D-39FA92C272D8

P698

Q35001598-18568DDA-8DFC-466F-A19D-39BE474023DD

P932

Q35001598-674D9DBA-87B9-4139-9F81-81C174EAAFAB

P356

BLOOD-2010-10-311456

P1433

P1476

Safety (toxicity), pharmacokin ...... uman IL-15 in rhesus macaques.

@en

P2093

Bonita R Bryant

http://www.w3.org/2001/XMLSchema#string

Carolyn K Goldman

http://www.w3.org/2001/XMLSchema#string

Enrico Lugli

http://www.w3.org/2001/XMLSchema#string

H Clifford Lane

http://www.w3.org/2001/XMLSchema#string

Jason L Yovandich

http://www.w3.org/2001/XMLSchema#string

Jean M Decker

http://www.w3.org/2001/XMLSchema#string

John M Pletcher

http://www.w3.org/2001/XMLSchema#string

Liyanage P Perera

http://www.w3.org/2001/XMLSchema#string

Mario Roederer

http://www.w3.org/2001/XMLSchema#string

Michael C Sneller

http://www.w3.org/2001/XMLSchema#string

P2860

IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice

Interleukin 15: biology and relevance to human disease.

Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy.

Transient and persistent effects of IL-15 on lymphocyte homeostasis in nonhuman primates

Interleukin-2 and interleukin-15: immunotherapy for cancer.

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

P304

4787-4795

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-10-311456

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P50

David E. Kleiner

P577

2011-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50347982

http://www.w3.org/2001/XMLSchema#string

P698

21385847

http://www.w3.org/2001/XMLSchema#string

P932

3100690

http://www.w3.org/2001/XMLSchema#string